“…It is a membrane protein with a single-pass transmembrane domain; however, it is predominantly extracellular, with a very short 5-amino acid intracellular cytoplasmic domain at its C-terminal end. PKHD1L1 has been identified as a potential biomarker or has been implicated in several cancers, including but not limited to: thyroid cancer (Zheng et al, 2019), lung adenocarcinoma (Kang et al, 2023; L. Wang et al, 2023), renal cell carcinoma (Yang et al, 2023), skin cutaneous melanoma (Kang et al, 2023), cervical cancer (Zou et al, 2022), squamous cell carcinoma (Song et al, 2021), and breast cancer (Saravia et al, 2019). Furthermore, rare pathogenic variants of PKHD1L1 have been linked to conditions such as schizophrenia (Shang et al, 2024), in studies involving human subjects, and anxiety-like traits in rodents (Chitre et al, 2023).…”